Under the radar investment opportunities aren't necessarily rare but rather are hard to find. And one unpolished gem could be Agentix Corp. (OTC: AGTX), a company we estimate to have between 200,000 and 1,500,000 shares in its public float and is nearing, at least we believe, commercialization of a comprehensive suite of health solutions for patients and consumers. In fact, an 8K filed last Friday makes the stock more exciting and shows that AGTX is indeed on the move.
In that announcement, AGTX confirmed that on May 21, 2021, it received notice of effectiveness of a certain License Agreement dated May 10, 20201, between its wholly-owned subsidiary, Applied BioPharma LLC, and National Health Research Institutes, a Taiwan, Republic of China, entity. According to the filing, AGTX purchased a worldwide, terminable, royalty-bearing, exclusive license for the technology and patent rights for all products related to pyrazole compounds to treat Type 2 diabetes, obesity, and fatty liver disease.
This technology is a peripherally restricted cannabinoid receptor 1 antagonist that has successfully completed preliminary pre-clinical and in vivo testing requirements for advancement into Phase I clinical trials. This deal can be significant for AGTX near and long term.
Remember, besides GW Pharma (which Jazz Pharma (NASDAQ: JAZZ) bought for $7.2 billion in February) bringing its CBD-based epilepsy drug to market, few, if any, others have gotten far into the FDA approval process. Moreover, research on this compound suggests it has a solid chance of getting approved for its targeted indications. Better still, the terms are favorable and come with patent protection for many of the claims extending out 20 years.
To those paying attention, the deal came after a few hints from the company earlier this year. And the next drop of news could send this low-float stock substantially higher.
Huge Insider Ownership
Keep this in mind, too. Insiders own roughly 92% of the stock...and they haven't been selling at these low prices. Moreover, since the start of the year, Agentix is higher by roughly 58%, albeit on anemic volume. Still, the trend since then has been notably higher, and at the moment, the trading pattern suggests that buyers are building positions. Better for them, according to the company's last SEC filing, there are no options, convertible notes, or outstanding warrants to dilute new and existing investors.
In fact, everything about AGTX sets up for a bullish run. Although quiet on the news front, AGTX provided investors a hint of its plans earlier this year when they published an update confident of meeting expectations for near-term revenue growth from its generic cannabinoid-based pharmaceutical products coupled with a proprietary delivery system. The deal last week adds more firepower to that initiative.
Better still, digging deeper into AGTX, they also expect to drive revenues from its mid and long-term programs that focus on developing small molecule pharmaceuticals targeting the G-protein coupled receptors of the endocannabinoid system.
Agentix has the assets to do just that.
Developing Products To Meet CBD-Based Demand
Indeed, investors should remain anxious ahead of the details on this new licensing agreement. However, keep in mind that Agentix is already developing synthetic agonists, inverse agonists, and antagonists, which modulate the endocannabinoid system (ECS). The ECS is a network of G-protein coupled receptors (GPCRs) that help regulate various metabolic and neurotransmission functions. By the way, that market may offer a golden opportunity to the company, noting that over 134 drugs approved worldwide currently target GPCR applications. Better news for Agentix is that the market is proven, with sales of these specific drugs generating several billion dollars annually in revenues.
Also, Agentix Corp. isn't going it alone. They have partnerships with leading academic and research institutions. Just as important, they have exclusively licensed patented, synthetically-derived, small molecule therapeutic candidates targeting the endocannabinoid GPCRs (CB1/CB2) to treat metabolic syndrome peripheral inflammation. From a timing perspective, Agentix is already advancing these therapeutic product candidates in clinical trials. That's good news.
Better still, they are also developing a series of health and wellness products that incorporate proprietary and proven nanotechnology similar to liposomal delivery systems, known as a cellular bio-complex, for the health & wellness markets. Once fully developed, the company expects to utilize these bio-complexes to create and produce pharma-grade products for more specific clinical (non-prescription and prescription) applications, such as arthritic joint pain, acne vulgaris, and onychomycosis.
A third money-shot is focused on developing pharmaceutical applications that target the human endocannabinoid system for treatments ranging from epilepsy, Type 2 diabetes, and acute kidney injury. These programs are already under development, ranging from design and discovery to pre-clinical evaluations. Notably, biological testing is being done with the support of leading universities and research institutions.
Deals Made Last Year Back In-Play
We'd be remiss to leave out another important program. Beyond the promise from its developing pipeline, Agentix expects to create value from its Master Development, License and Supply Agreement agreement with BIONOVA Labs, Inc., a Long Island City, NY, company. The deal, signed in July of 2020, structures terms for the co-development and commercialization of proprietary nanotechnology based on BIONOVA's NuCell Technology.
The deal with BIONOVA can be valuable from two perspectives. First, BIONOVA's approach differs from industrial nanotechnology and the nanotechnological processes in the health care industry, which focuses only on the particle sizes of matter. Second, BIONOVA products do not contain any engineered nano-materials but include a combination of many ingredients (most ordinarily produced by the human body) that are presented in "nano and pico-amounts" (physiological amounts) - at a level that is most efficient for metabolic uptake in the tissue(s). This unique technology is utilized only by BIONOVA. And it may offer best-in-class results.
Also important to note is that the partnership with BIONOVA includes developing novel Cannabinoid-Biocomplexes that include customized formulations for targeted delivery of bio-pharmacological elements for various clinical indications already identified in Agentix's business plan. Thus, these assets can be quickly accretive to product development timelines.
In other words, the partnership can accelerate revenue-generating timelines.
Translating Growth In 2020 Into Value In 2021
For those just now introduced to Agentix, the opportunities in play are adding up nicely. While the company doesn't put out much news, they effectively put the pieces together to build an impressive brand.
Moreover, they have multiple shots on goal, a pipeline that targets compelling medical needs, and benefits from its management and scientific advisory team capable of making informed strategic decisions. The sum of the parts translates to growth.
The 8K last week appears to have gone under the radar. But, oversights by some create opportunities for others. And with near-term catalysts potentially on the way, this low-float stock can move quickly. It's unlikely that AGTX will remain under the radar much longer.
Disclaimers: Hawk Point Media is responsible for the production and distribution of this content. Hawk Point Media is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by Hawk Point Media is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Hawk Point Media be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Hawk Point Media, its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Media Contact
Company Name: Hawk Point Media
Contact Person: KL Feigeles
Email: editorial@hawkpointmedia.com
City: Miami Beach
State: Florida
Country: United States
Website: https://www.greenlightstocks.com
